Maxim Group analyst Jason McCarthy has maintained their bullish stance on PSTV stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Plus Therapeutics’ financial and strategic positioning. The company has secured a $17.6 million grant from the Cancer Prevention & Research Institute of Texas and a $50 million stock purchase agreement, which are expected to fund operations into mid-2026. This financial stability is further supported by a recent restructuring of its financing, which reduces potential dilution and transforms it into a less dilutive form, providing a more favorable outlook for investors.
Additionally, Plus Therapeutics is advancing its clinical trials, including the P2 ReSPECT-GBM study and the P1 ReSPECT-LM study, both of which are progressing towards significant milestones. The imminent commercial launch of CNSide as a standalone diagnostic for leptomeningeal metastases is anticipated to generate meaningful revenue, driven by physician familiarity and an expanded data package that supports value-based reimbursement. These strategic developments, coupled with the company’s financial maneuvers, underpin McCarthy’s optimistic outlook and Buy rating for Plus Therapeutics.
According to TipRanks, McCarthy is an analyst with an average return of -18.2% and a 32.53% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and OS Therapies Incorporated.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.